Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.40 |
| ▸ | ACHE | P22303 | 5/20 | 0.40 |
| ▸ | GPR3 | P46089 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL4485013 | 0.84 | KCNH2 (0.40) | KDM4EALDH1A1GAAHPGDKCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL31472680 | 0.83 | KCNH2 (0.41) | KDM4EALDH1A1GAAHPGDKCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL4497025 | 0.83 | KCNH2 (0.41) | KDM4EALDH1A1GAAHPGDKCNH2 | |
| SCHEMBL382590 | 0.83 | KDM4E (0.48) | KDM4EALDH1A1GAAHPGDKCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL3855070 | 0.82 | KCNH2 (0.43) | KCNH2ACHEGPR3 | |
| SCHEMBL30929898 | 0.81 | ACHE (0.47) | KDM4EALDH1A1GAAHPGDACHE | |
| SCHEMBL1044982 | 0.81 | ACHE (0.47) | KDM4EALDH1A1GAAHPGDACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL6554225 | 0.81 | ACHE (0.46) | KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL11070399 | 0.81 | KCNH2 (0.38) | KCNH2ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL4887199 | 0.81 | KCNH2 (0.42) | KDM4EALDH1A1GAAHPGDKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249627-A1 | QUINOLINIUM SALTS AND DERIVATIVES THEREOF FOR TREATING FLAVIVIRUS INFECTION | PLEX PHARMACEUTICALS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | IMMUSOL INCORPORATED (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1841428-A1 | NOVEL QUINOLINIUM SALTS AND DERIVATIVES | Immusol Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006078754-A1 | NOVEL QUINOLINIUM SALTS AND DERIVATIVES | IMMUSOL INCORPORATED (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | NQO2, MCL1, KRAS | KDM4E 2336/4885ALDH1A1 3206/4885GAA 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.